The future of ctDNA in cancer care is promising, with ongoing research focused on improving the sensitivity and specificity of detection methods. Advances in technology, such as ultra-deep sequencing and novel biomarkers, may enhance the utility of ctDNA in early detection, treatment monitoring, and personalized medicine. Additionally, integrating ctDNA analysis with other diagnostic modalities, like imaging and protein biomarkers, could provide a more comprehensive approach to cancer management.
